Anti-Neoplastic Agents Market to Witness Significant Growth of USD $197.68 Billion with 8.8% CAGR by 2029
Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations
What Is the Growth Potential of the Anti-Neoplastic Agents Market in the Next Decade?
The anti-neoplastic agents market size has grown strongly in recent years. It will grow from $130.01 billion in 2024 to $140.9 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing cancer incidence, growing demand for therapies, rising demand for minimally invasive cancer treatments, demand for affordable anti-neoplastic treatments.
The anti-neoplastic agents market size is expected to see strong growth in the next few years. It will grow to $197.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to patient education and awareness, government initiative, growing demand for personalized cancer treatment, growing focus on quality of life in cancer treatment. Major trends in the forecast period include advancements in oncology research, development of targeted therapies, biotechnology innovation, advancements in diagnostic tools.
Claim your free report sample now:
What Are the Major Drivers Influencing the Anti-Neoplastic Agents Market?
The increasing number of cancer cases is expected to propel the growth of the antineoplastic agent market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their normal boundaries and either spread to other organs or invade neighboring body parts. Antineoplastic agents play an essential role in cancer treatment by inhibiting cancer cell growth and division through various mechanisms, including DNA (Deoxyribonucleic acid) damage, cell cycle disruption and interference with crucial cellular pathways. For instance, in February 2024, according to the latest estimates of the global burden of cancer by the International Agency for Research on Cancer (IARC), a France-based international agency that promotes international collaboration in cancer research, the cancer burden is expected to grow to more than 35 million in 2050, a 77% increase over the estimated 20 million in 2022. Therefore, the increasing number of cancer cases is driving the growth of the antineoplastic agent market.
Which Segment Holds the Largest Share in the Anti-Neoplastic Agents Market?
The anti-neoplastic agents market covered in this report is segmented –
1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous
2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers
Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists
3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids
4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents
What Are the Major Trends Impacting the Anti-Neoplastic Agents Market?
Major companies operating in the anti-neoplastic agent market are focused on developing clinical practices to sustain their position in the market. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceutical corporation, announced the Food and Drug Administration's (FDA) approval of Pluvicto, a first targeted radioligand therapy for the treatment of progressive, PSMA (Prostate-specific membrane antigen) positive metastatic castration-resistant prostate cancer (mCRPC). It is recommended to provide 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks for a maximum of six doses or until disease progression or intolerable toxicity, whichever comes first. Based on PSMA expression in tumors, patients with previously treated mCRPC should be chosen for treatment with Pluvicto utilizing Locametz or another authorized PSMA-11 imaging agent.
Which Major Companies Are Operating in the Anti-Neoplastic Agents Market?
Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.
Get the full anti-neoplastic agents market report here:
Which Region Is Expected to Lead the Anti-Neoplastic Agents Market by 2029?
North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment